Compounded medication and FDA-approved medicine: key differences
Compounding is not FDA approval. FDA says compounded drugs are not FDA-approved, which means FDA does not verify their safety, effectiveness or quality before they are marketed. An FDA-approved medicine has been through that review. This page explains the difference in broad terms. It is not legal advice and it does not say which product to use.
Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)
Quick answer
Compounding is not FDA approval. FDA says compounded drugs are not FDA-approved, which means FDA does not verify their safety, effectiveness or quality before they are marketed. An FDA-approved medicine has been through that review. This page explains the difference in broad terms. It is not legal advice and it does not say which product to use.
What the difference is
- FDA-approved drugs are reviewed by FDA for safety, effectiveness and quality. Brand names such as Wegovy and Zepbound are FDA-approved.
- Generic drugs are approved by FDA and must establish therapeutic equivalence to the brand drug. A generic is not a compounded drug.
- Compounded drugs are not FDA-approved. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an approved drug, and that unnecessary use may expose patients to serious risk, such as contamination or too much or too little active ingredient.
Source: FDA, compounding and the FDA: questions and answers.
Why compounding exists
In broad terms, federal law allows compounding by a licensed pharmacist in a state-licensed pharmacy (section 503A), when it is based on a valid patient-specific prescription, and by outsourcing facilities (section 503B), which are inspected by FDA and held to current good manufacturing practice standards. A compounded drug might be appropriate when a patient’s medical need cannot be met by an approved drug. Availability alone does not establish permission to compound: federal conditions, including restrictions on essentially copying approved products, still apply. Sources: FDA, human drug compounding laws; FDA, concerns with unapproved GLP-1 drugs.
Where people get GLP-1 products

Where GLP-1 users got their drugs
In a national KFF poll in October and November 2025, among adults who had ever taken a GLP-1 drug, 76% said they got it or a prescription from one of their doctors, 17% from an online provider or website, and 9% from a medical spa or aesthetic medical center (people could pick more than one). In April and May 2024 the shares were 79%, 11% and 10%. KFF notes that some people seek generic or compounded versions from sources such as medical spas or compounding pharmacies, but the poll does not show which products people received. Sources: KFF poll, Nov 2025; KFF poll, May 2024.
What FDA has said about GLP-1 products
- FDA declared the semaglutide injection shortage resolved on February 21, 2025 (FDA order). Its shortage file records the tirzepatide injection shortage as resolved in December 2024 (FDA memo). Local supply gaps can still occur. Compounding rules that depend on shortage status can change, so check FDA’s current pages and your state pharmacy board.
- FDA has received reports of adverse events, some needing hospitalization, linked to dosing errors with compounded semaglutide injection. In many reports patients drew up five to 20 times the intended dose from a multiple-dose vial, often unfamiliar with measuring with a syringe and confused by milliliters, milligrams and “units.” Source: FDA alert on dosing errors.
- FDA has also received reports tied to prescriptions above label doses, more frequent dosing or faster titration, with symptoms including nausea, vomiting, diarrhea, abdominal pain and constipation. Source: FDA concerns page.
- Compounded products can differ from approved ones in packaging, containers and concentration, which can make errors more likely.
Questions about a specific product
If you are offered a compounded or non-brand product, you can ask your prescriber and pharmacist:
- Who is the pharmacy or outsourcing facility, and is it licensed? Check your state pharmacy board.
- Is this FDA-approved, a generic, or compounded, and why this choice?
- What are the active ingredients, concentration, container and expiration or discard date?
- What are the directions, and what syringe or device is used? Ask them to show you how to measure the intended dose, since FDA encourages this.
- Is this a patient-specific prescription?
- What do I do about problems, and whom do I call?
What to verify
Check current FDA information and your state pharmacy board. Treatment decisions belong with your prescriber. If the product or supply seems uncertain, ask your pharmacist before using it and report adverse events to FDA.
What this does not establish
This page does not say that every compounded product is unsafe, or that approved products never have problems. It does not describe your state’s rules and is not legal advice. Regulatory status can change.
FAQs
What should I check about compounded and FDA-approved medicine? Which category your product is, who made it, its ingredients and concentration, its directions, and why it was chosen.
Which official instructions or documents should I use? For approved products, the FDA label, Medication Guide and Instructions for Use. For compounded products, FDA’s compounding pages, your pharmacy’s information and your prescriber’s directions.
Who should I contact if the product or supply seems uncertain? Your pharmacist first, your prescriber, your state pharmacy board for licensing, and FDA for adverse events.
Sources
- FDA, compounding and the FDA: questions and answers
- FDA, human drug compounding laws
- FDA, concerns with unapproved GLP-1 drugs used for weight loss
- FDA alert, dosing errors with compounded semaglutide
- FDA declaratory order, semaglutide shortage resolved
- FDA CDER memo, tirzepatide shortage resolved
- KFF Health Tracking Poll, November 2025
- KFF Health Tracking Poll, May 2024